Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007
Date:11/13/2007

Company Provides Update on Oncology Pipeline Progress

SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced financial results for the three and nine months ended September 30, 2007. For the three months ended September 30, 2007, the Company posted revenues of $7.6 million and a net loss of $4.8 million. For the nine months ended September 30, 2007, revenues were $27.1 million and the net loss was $9.9 million. Cash, cash equivalents and short-term investments totaled $21.4 million at September 30, 2007 compared to $33.9 million at December 31, 2006.

Pipeline Update

* The IND submission for SGX523, the Company's lead MET inhibitor, is

expected to be made prior to year end, with Phase 1 clinical trials

anticipated to begin in early 2008. The Company is also moving

forward a number of other MET inhibitors with differing profiles to

SGX523 to further broaden the scope of the program.

* SGX393, a BCR-ABL inhibitor the Company is developing for the

relapsed/refractory Chronic Myelogenous Leukemia (CML) patient

population, is in formal toxicology studies and an IND submission is

targeted for the first half of 2008. Initial clinical studies are

planned to focus on patients with the most clinically challenging

CML mutation, known as the T315I mutant.

* Other BCR-ABL inhibitors, with potential to target the front-line

patient population, are undergoing preclinical studies in

collaboration with Novartis.

"We are excited about the progress of our pipeline candidates this quarter, particularly in our M
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Steven Reinberg HealthDay ... Infants who quickly add weight and length may be showing ... suggests. In adults, certain genes have been linked to ... proportionate gains in fat and lean muscle, the researchers said. ... heavier and taller. By ages 2 and 3, however, these ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Women having children at older ages and the growing ... in the birth of twins: In 2009, one in every ... compared with one in every 53 in 1980. The ... at the 14th Congress of the International Society of Twin ...
... Computer scientists and biologists in the Data ... a rare collaboration between the two very different fields ... modern medicine. Their unique partnership has uncovered a new ... of human tissue to its corresponding biological function. The ...
... research team led by scientists from Singapore Immunology Network ... (A*STAR) discovered that a special class of fatty molecules ... immune cells. This study sheds light on how recognition ... infection, allergic reactions, autoimmune diseases and cancer. More importantly, ...
... -- Measles vaccines don,t increase the risk of febrile seizures ... study. Febrile seizures are brief, fever-related convulsions that are ... or other seizure disorders. The study, conducted by the ... Centers for Disease Control and Prevention, looked at data from ...
... 2, 2012)Scientists at Fox Chase Cancer Center have uncovered more ... makes new proteins can lead to blood and other cancers. ... Annual Meeting 2012 on Monday, April 2, may one day ... "These findings help explain how mutations in one class of ...
... research developments to reprogram scar tissue resulting from ... at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held ... of Imperial College in London. In a keynote ... described as a "game changer" with the potential to revolutionise ...
Cached Medicine News:Health News:Seeing double: 1 in 30 babies born in US is a twin 2Health News:From beaker to bits: Collaboration creates computational model of human tissue 2Health News:From beaker to bits: Collaboration creates computational model of human tissue 3Health News:From beaker to bits: Collaboration creates computational model of human tissue 4Health News:A*STAR scientists discover special class of natural fats stimulates immune cells to fight diseases 2Health News:Measles Vaccines Won't Raise Seizure Risk in Young Kids: Study 2Health News:Researchers uncover new clues to the development of blood and other cancers 2Health News:Transforming scar tissue into beating hearts: The next instalment 2Health News:Transforming scar tissue into beating hearts: The next instalment 3Health News:Transforming scar tissue into beating hearts: The next instalment 4
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... 30, 2011 Roche announced today the opening of ... campus in Nutley, N.J. The Roche Center of Excellence ... safety studies, and Phase 1 and 2 clinical studies. ... process potent compounds into medicines for clinical trials. ...
... 30, 2011 ViroPharma Incorporated (NASDAQ: VPHM ... Intellect Neurosciences, Inc. (OTCBB: ILNS) to its clinical stage ... Friedreich,s Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease. ... a naturally occurring, small molecule that has potent anti-oxidant ...
Cached Medicine Technology:Roche Opens New Center of Excellence Facility 2ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 2ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 3ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: